{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:09:31Z","timestamp":1770970171988,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,10,21]],"date-time":"2004-10-21T00:00:00Z","timestamp":1098316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1007\/s00213-004-2032-2","type":"journal-article","created":{"date-parts":[[2004,10,20]],"date-time":"2004-10-20T17:14:25Z","timestamp":1098292465000},"page":"144-150","source":"Crossref","is-referenced-by-count":96,"title":["A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients"],"prefix":"10.1007","volume":"179","author":[{"given":"Donald C.","family":"Goff","sequence":"first","affiliation":[]},{"given":"Lawrence","family":"Herz","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Posever","sequence":"additional","affiliation":[]},{"given":"Vivian","family":"Shih","sequence":"additional","affiliation":[]},{"given":"Guochuan","family":"Tsai","sequence":"additional","affiliation":[]},{"given":"David C.","family":"Henderson","sequence":"additional","affiliation":[]},{"given":"Oliver","family":"Freudenreich","sequence":"additional","affiliation":[]},{"given":"A. Eden","family":"Evins","sequence":"additional","affiliation":[]},{"given":"Iftah","family":"Yovel","sequence":"additional","affiliation":[]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"David","family":"Schoenfeld","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2004,10,21]]},"reference":[{"key":"CR1","unstructured":"Andreasen N (1984) Modified scale for the assessment of negative symptoms. National Institutes of Mental Health publication ADEM 9?102"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0006-3223(96)00311-3","volume":"40","author":"BN Berckel van","year":"1996","unstructured":"van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS (1996) Efficacy and tolerance of d-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298?1300","journal-title":"Biol Psychiatry"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0893-133X(99)00014-7","volume":"21","author":"BNM Berckel van","year":"1999","unstructured":"van Berckel BNM, Evenblij CN, van Loon BJAM, Maas MF, van der Geld MAM, Wynne HJ, van Ree JM, Kahn RS (1999) d-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21:203?210","journal-title":"Neuropsychopharmacology"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01276429","volume":"95","author":"NG Cascella","year":"1994","unstructured":"Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994) d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm [Gen Sect] 95:105?111","journal-title":"J Neural Transm [Gen Sect]"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0006-8993(91)91668-Q","volume":"565","author":"I Chessell","year":"1991","unstructured":"Chessell I, Procter A, Francis P, Bowen D (1991) d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res 565:345?348","journal-title":"Brain Res"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.115.11.1025","volume":"115","author":"GE Crane","year":"1959","unstructured":"Crane GE (1959) Cycloserine as an antidepressant agent. Am J Psychiatry 115:1025?1026","journal-title":"Am J Psychiatry"},{"key":"CR7","first-page":"597","volume":"50","author":"W Danysz","year":"1998","unstructured":"Danysz W, Parsons C (1998) glycine and N-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597?664","journal-title":"Pharmacol Rev"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0006-3223(99)00133-X","volume":"47","author":"DC D?Souza","year":"2000","unstructured":"D?Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH (2000) IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry 47:450?462","journal-title":"Biol Psychiatry"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","volume":"157","author":"A Evins","year":"2000","unstructured":"Evins A, Fitzgerald S, Wine L, Roselli R, Goff D (2000) A placebo controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826?828","journal-title":"Am J Psychiatry"},{"key":"CR10","first-page":"269","volume":"77","author":"C Ganote","year":"1974","unstructured":"Ganote C, Peterson D, Carone F (1974) The nature of d-serine-induced nephrotoxicity. Am J Pathol 77:269?282","journal-title":"Am J Pathol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","volume":"158","author":"DC Goff","year":"2001","unstructured":"Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367?1377","journal-title":"Am J Psychiatry"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","volume":"152","author":"DC Goff","year":"1995","unstructured":"Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213?1215","journal-title":"Am J Psychiatry"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","volume":"153","author":"DC Goff","year":"1996","unstructured":"Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) d-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628?1630","journal-title":"Am J Psychiatry"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","volume":"45","author":"D Goff","year":"1999","unstructured":"Goff D, Henderson D, Evins A, Amico E (1999a) A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512?514","journal-title":"Biol Psychiatry"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","volume":"56","author":"D Goff","year":"1999","unstructured":"Goff D, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld D, Hayden D, McCarley R, Coyle J (1999b) A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21?27","journal-title":"Arch Gen Psychiatry"},{"key":"CR17","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU Assessment manual for psychopharmacology. US Department of Health, Education, and Welfare","DOI":"10.1037\/e591322011-001"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"MA Hamilton","year":"1960","unstructured":"Hamilton MA (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56?62","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","volume":"10","author":"DW Heinrichs","year":"1984","unstructured":"Heinrichs DW, Hanlon TE, Carpenter WT (1984) The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388?396","journal-title":"Schizophr Bull"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1113\/jphysiol.1990.sp018288","volume":"430","author":"G Henderson","year":"1990","unstructured":"Henderson G, Johnson JW, Ascher P (1990) Competitive antagonists and partial agonists at the glycine modulatory site of the mouse N-methyl-d-aspartate receptor. J Physiol 430:189?212","journal-title":"J Physiol"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(03)00129-4","volume":"66","author":"U Heresco-Levy","year":"2004","unstructured":"Heresco-Levy U, Javitt D (2004) Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res 66:89?96","journal-title":"Schizophr Res"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1192\/bjp.169.5.610","volume":"169","author":"U Heresco-Levy","year":"1996","unstructured":"Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610?617","journal-title":"Br J Psychiatry"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1017\/S1461145798001242","volume":"3","author":"U Heresco-Levy","year":"1998","unstructured":"Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J (1998) Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 3:131?135","journal-title":"Int J Neuropsychopharmacol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","volume":"56","author":"U Heresco-Levy","year":"1999","unstructured":"Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29?36","journal-title":"Arch Gen Psychiatry"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1176\/appi.ajp.159.3.480","volume":"159","author":"U Heresco-Levy","year":"2002","unstructured":"Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480?482","journal-title":"Am J Psychiatry"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","volume":"151","author":"DC Javitt","year":"1994","unstructured":"Javitt DC, Zylberman I, Zukin SR, Heresco LU, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234?1236","journal-title":"Am J Psychiatry"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ac60109a012","volume":"28","author":"LR Jones","year":"1956","unstructured":"Jones LR (1956) Colorimetric determination of cycloserine, a new antibiotic. Anal Chem 28:39?41","journal-title":"Anal Chem"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-59259-436-8_5","volume-title":"Method of protein microcharacterization","author":"BN Jones","year":"1986","unstructured":"Jones BN (1986) Amino acids by ophthaldialdehyde precolumn derivatization and reverse-phase HPLC. In: Shively JE (ed) Method of protein microcharacterization. Humana, Clifton, pp 121?151"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261?276","journal-title":"Schizophr Bull"},{"key":"CR29","first-page":"438","volume":"73","author":"IV Kendig","year":"1956","unstructured":"Kendig IV, Charen S, Lepine LT (1956) Psychological side-effects induced by cycloserine in the treatment of pulmonary tuberculosis. Am Rev Tuberc 73:438?441","journal-title":"Am Rev Tuberc"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(89)90153-4","volume":"30","author":"B Kirkpatrick","year":"1989","unstructured":"Kirkpatrick B, Buchanan R, McKenney P (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119?123","journal-title":"Psychiatry Res"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.1962.01720060019002","volume":"7","author":"L Luborsky","year":"1962","unstructured":"Luborsky L (1962) Clinicians? judgments of mental health. Arch Gen Psychiatry 7:407?417","journal-title":"Arch Gen Psychiatry"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","volume":"156","author":"S Potkin","year":"1999","unstructured":"Potkin S, Jin Y, Bunney B, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145?147","journal-title":"Am J Psychiatry"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0010-440X(70)90207-5","volume":"11","author":"J Simeon","year":"1970","unstructured":"Simeon J, Fink M, Itil T, Ponce D (1970) d-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry 11:80?88","journal-title":"Comp Psychiatry"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JWS (1970) Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl 212:11?19","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","volume":"44","author":"G Tsai","year":"1998","unstructured":"Tsai G, Yang P, Chung L-C, Lange N, Coyle J (1998) d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081?1089","journal-title":"Biol Psychiatry"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","volume":"156","author":"G Tsai","year":"1999","unstructured":"Tsai G, Yang P, Chung L-C, Tsai I-C, Tsai C-W, Coyle J (1999) d-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822?1825","journal-title":"Am J Psychiatry"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0006-8993(90)90745-W","volume":"510","author":"GB Watson","year":"1990","unstructured":"Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) d-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158?160","journal-title":"Brain Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-004-2032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-004-2032-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-004-2032-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T16:33:43Z","timestamp":1682786023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-004-2032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1007\/s00213-004-2032-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,21]]}}}